市場調查報告書

非類鴉片物質疼痛貼片市場:成長,趨勢,預測

Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 704955
出版日期 內容資訊 英文 120 Pages
商品交期: 2-3個工作天內
價格
非類鴉片物質疼痛貼片市場:成長,趨勢,預測 Non-opioid Pain Patch Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年02月01日內容資訊: 英文 120 Pages
簡介

疼痛,比心血管疾病、癌症、糖尿病的組合帶給社會經濟系統更大的影響。國際癌症研究機關(IARC),預測至2030年將新增2,170萬名癌症患者和1,300萬名癌症死者。同樣,心血管疾病(CVD),是全球成人族群的主要死因之一。慢性疼痛,以各種方法發病。譬如,外傷,提起重物造成的事故和腰的負擔,胰炎,脊椎疾病,關節炎,自體免疫疾病等的基礎疾病,以及纖維肌痛症和持續性的偏頭痛等。非類鴉片物質疼痛貼片,沒有像Fentanyl貼片等類鴉片物質藥物貼片有中毒的風險,藥物長期間放出,有助於更長期的疼痛管理。

本報告提供全球非類鴉片物質止痛貼片市場調查,市場概要,各貼片類型、通路、地區的市場規模的變化與預測,市場趨勢,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場細分化

  • 貼片各類型
    • 利多卡因貼片
    • 雙氯芬酸鈉貼片
    • 辣椒素貼片
    • 酮洛芬貼片
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Clarion Brands Inc.
    • Endo Pharmaceuticals Inc.
    • Hisamitsu Pharmaceutical Co. Inc.
    • Sanofi SA
    • Sorrento Therapeutics (SCILEX Pharmaceuticals)
    • TEH SENG Pharmaceutical Mfg Co
    • Teikoku Seiyaku Co. Ltd.
    • Teva Pharmaceuticals Industries Ltd.
    • Veridian Healthcare

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 64062

Pain has a deeper impact on the socio-economic system than the combination of cardiovascular diseases, cancer, and diabetes together. The International Agency for Research on Cancer (IARC) predicts that, by 2030, the global burden is expected to increase to 21.7 million new cancer cases and 13 million cancer deaths. Similarly, cardiovascular disease (CVD) is one of the main causes of death among the adult population, globally. Chronic pain initiates in numerous ways, for instance, from trauma which could include an accident or back strain due to heavy lifting among other ways, an underlying disease like pancreatitis, spine disease, arthritis, and autoimmune diseases, or it can occur with fibromyalgia or persistent migraines. As per, CDC around 43% of the population suffer from pain on some days and around 20% of the population suffer from pain every day or on most days. There are numerous risk factors for chronic pain. Non-opioid patches are more preferable because it does not involve the risk of addiction as with opioid drug patches like fentanyl patches and also the drugs is released over a long period of time, therefore, helping in managing the pain for a longer duration and considered as a valuable driver for this market.

However, availability of alternative treatments and low adoption rate of non-opioid pain patch due to unawareness is expected to impede the growth of non-opioid pain patch market.

Key Market Trends

Lidocaine Patches Segment is Expected to Show Better Growth in the Forecast Years

Based on type, the market is segmented into lidocaine patches, diclofenac patches, capsaicin patches, ketoprofen patches, and others. Lidocaine patches are considered as the most commonly available patch for the treatment of chronic and acute pain. According to the American Academy of Pain Medicine (AAPM), chronic pain affects approximately 1.5 billion people worldwide with prevalence increasing with age. The proportion of the world's population over 60 years will nearly double from 12% to 22%, between 2015 and 2050, as per WHO estimates. Lidocaine patches are recommended as first-line therapy for the treatment of neuropathic pain in older patients, which is expected to boost the market growth. Furthermore, the increasing burden of diseases, along with safety profile and efficacy associated with lidocaine patches are expected to drive the market growth during the forecast period.

North America is Expected to Dominate the Non-opioid Pain Patch Market

North America is expected to retain its dominance in this market. chronic pain is one of the primary factors responsible for the growth of the market. According to the National Institute of Health (NIH), in 2016, around 20% of US adults were suffering from chronic pain and 8% had high impact, which at least limits one major life activity in the patient. In addition, the countries in North America are increasingly facing scrutiny on the opioid crises issue, from the government authorities, which in turn are expected to benefit the rise of non-opioid alternatives. Thus, rising disease burden is further pushing the need for effective and quick treatment options which is expected to propel the growth of the market, over the forecast period.

Competitive Landscape

The global players in the non-opioid pain patch market are - Clarion Brands Inc., Endo Pharmaceuticals, Hisamitsu Pharmaceutical, Sanofi, Sorrento Therapeutics (SCILEX Pharmaceuticals), TEH SENG Pharmaceutical, Teikoku Seiyaku, Teva Pharmaceuticals, and Veridian Healthcare.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Pain-Related Disorders
    • 4.2.2 Rising R&D in Pain Management Treatments
    • 4.2.3 Benefits Associated with Non-opioid Pain Patches over Conventional Medications
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatments
    • 4.3.2 Low Adoption Rate of Non-opioid Pain Patch due to Unawareness
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Patch Type
    • 5.1.1 Lidocaine Patches
    • 5.1.2 Diclofenac Patches
    • 5.1.3 Capsaicin Patches
    • 5.1.4 Ketoprofen Patches
    • 5.1.5 Others
  • 5.2 By Distribution Channel
    • 5.2.1 Hospital Pharmacies
    • 5.2.2 Retail Pharmacies
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clarion Brands Inc.
    • 6.1.2 Endo Pharmaceuticals Inc.
    • 6.1.3 Hisamitsu Pharmaceutical Co. Inc.
    • 6.1.4 Sanofi S.A.
    • 6.1.5 Sorrento Therapeutics (SCILEX Pharmaceuticals)
    • 6.1.6 TEH SENG Pharmaceutical Mfg Co
    • 6.1.7 Teikoku Seiyaku Co. Ltd.
    • 6.1.8 Teva Pharmaceuticals Industries Ltd.
    • 6.1.9 Veridian Healthcare

7 MARKET OPPORTUNITIES AND FUTURE TRENDS